Galapagos (GLPG) Expected to Announce Earnings on Wednesday

Galapagos (NASDAQ:GLPG) is expected to issue its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of $0.85 per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 7:00 AM ET.

Galapagos Stock Up 1.1%

NASDAQ:GLPG opened at $34.60 on Wednesday. Galapagos has a one year low of $22.36 and a one year high of $37.78. The stock has a 50 day moving average price of $32.78 and a 200 day moving average price of $32.61.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on GLPG. Weiss Ratings reiterated a “sell (d)” rating on shares of Galapagos in a report on Thursday, January 22nd. Sanford C. Bernstein began coverage on Galapagos in a research report on Wednesday, November 26th. They issued a “hold” rating on the stock. Leerink Partners raised Galapagos from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 22nd. Royal Bank Of Canada upped their target price on shares of Galapagos from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Friday, November 7th. Finally, Wall Street Zen upgraded shares of Galapagos from a “sell” rating to a “hold” rating in a research note on Tuesday, December 30th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $31.33.

Institutional Investors Weigh In On Galapagos

A number of hedge funds and other institutional investors have recently modified their holdings of GLPG. Bank of America Corp DE boosted its stake in Galapagos by 2.1% in the 3rd quarter. Bank of America Corp DE now owns 30,949 shares of the biotechnology company’s stock worth $1,072,000 after buying an additional 643 shares during the last quarter. Aquatic Capital Management LLC boosted its position in shares of Galapagos by 63.6% in the third quarter. Aquatic Capital Management LLC now owns 17,516 shares of the biotechnology company’s stock worth $607,000 after acquiring an additional 6,807 shares during the last quarter. Two Sigma Investments LP grew its holdings in Galapagos by 3.7% in the third quarter. Two Sigma Investments LP now owns 22,459 shares of the biotechnology company’s stock valued at $778,000 after purchasing an additional 800 shares during the period. BNP Paribas Financial Markets increased its position in Galapagos by 81.0% during the third quarter. BNP Paribas Financial Markets now owns 11,854 shares of the biotechnology company’s stock worth $411,000 after purchasing an additional 5,305 shares during the last quarter. Finally, Engineers Gate Manager LP acquired a new position in Galapagos during the second quarter worth approximately $560,000. 32.46% of the stock is currently owned by institutional investors and hedge funds.

Galapagos Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.